Physico-chemical properties and the structure of dermatan sulfate fractions purified from plasma after oral administration in healthy human volunteers

Thrombosis and Haemostasis

Volumn 75, Issue 3, 1996, Pages 491-496

  Volpi, Nicola ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATAN SULFATE; DISACCHARIDE; IDURONIC ACID; THROMBIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG PURIFICATION; DRUG STRUCTURE; DRUG SULFATION; FEMALE; GEL ELECTROPHORESIS; HUMAN; HUMAN EXPERIMENT; MALE; MOLECULAR WEIGHT; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SWINE;

EID: 0029872865     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650303     Document Type: Article

References (38)

1. Mammen EF, Walenga JM, Fareed J. Seminars in thrombosis and hemostasis, Thieme Medical Publishers, New York, Stuttgard, 1991; Vol. 17 suppl. 1-2.
2. Scott JE. Dermatan sulphate proteoglycans. Portland Press, London. U.K., 1993.
3. Al-Hakim A, Linhardt RJ. Capillary electrophoresis for the analysis of chondroitin sulfate- and dermatan sulfate-derived disaccharides. Analyt Biochem 1991; 195: 68-73.
4. Maimone MM, Tollefsen DM. Structure of a dermatan sulfate hexasaccharide that binds to heparin cofactor II with high affinity. J Biol Chem 1990; 265: 18263-71.
5. Volpi N. Dermatan sulfate from beef mucosa: structure, physicochemical and biological properties of fractions prepared by chemical depolymerization and anion-exchange chromatography. Carb Res 1994; 255: 133-44.
6. Ryan KE, Lane DA, Flynn A, Ireland H, Boisclair M, Shepperd J, Curtis JR. Antithrombotic properties of dermatan sulphate (MF 701) in haemodialysis for chronic renal failure. Thromb Haemost 1992; 68: 563-9.
7. Barbanti M, Calanni F, Milani MR, Marchi E, Semeraro N, Colucci M. Therapeutic effect of a low molecular weight dermatan sulphate (desmin 370) in rat venous thrombosis - Evidence for an anticoagulant-independent mechanism. Thromb Haemost 1993; 69: 147-51.
8. Bendayan P, Boccalon H, Dupouy D, Boncu B. Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins. Thromb Haemost 1994; 71: 576-80.
9. Fernandez F, Van Ryn J, Ofosu FA, Hirsh J, Buchanan MR. The haemorrhagic and antithrombotic effects of dermatan sulphate. Br J Haematol 1986, 64: 309-17.
10. Dol F, Houin G, Rostin M, Montastruc JL, Dupouy D, Gianese F, Sié P, Boneu B. Pharmacodynamics and pharmacokinetics of dermatan suifate in humans. Blood 1989; 74: 1577-82.
11. Dawes J, McLaren M, Forbes C, Belch JJF, Lane DA, Bray B, McEwen J, Houin G, Gianese F. The pharmacokinetics of dermatan sulphate MF701 in healthy human volunteers. Br J Clin Pharmac 1991; 32: 361-6.
12. Dawes J, Hudson BA, Pepper DS. The absorption, clearance and metabolic fate of dermatan sulphate administered to man - studies using a radioiodinated derivative. Thromb Haemost 1989; 62: 945-9.
13. Imbimbo BP, Sié P, Agnelli G, Saivin S, Dupouy D, Damiani M, Houin G, Gianese F. Intramuscular dermatan sulfate MF701 in patients with hip fracture: relationship between pharmacokinetics and antithrombotic efficacy. Thromb Haemost 1994; 71: 553-7.
14. Volpi N. Fractionation of heparin, dermatan sulfate, and chondroitin sulfate by sequential precipitation: a method to purify a single glycosaminoglycan species from a mixture. Analyt Biochem 1994; 218: 382-91.
15. Shively JE, Conrad HE. Formation of anhydrosugars in the chemical depolymerization of heparin. Biochemistry 1976; 15: 3932-42.
16. Poblacion CA, Michelacci YM. Structural differences of dermatan sulfates from different origins. Carb Res 1986; 147: 87-100.
17. Volpi N. "Fast moving" and "slow moving" heparins, dermatan sulfate, and chondroitin sulfate: qualitative and quantitative analysis by agarose-gel electrophoresis. Carb Res 1993; 247: 263-78.
18. Cappelletti R, De Rosso M, Chiarugu VP. A new electrophoretic method for the complete separation of all known animal glycosaminoglycans in a monodimensional run. Analyt Biochem 1979; 99: 311-5.
19. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin-phenol method. J Biol Chem 1951; 193: 317-23.
20. Volpi N, Cusmano M, Venturelli T. Qualitative and quantitative studies of heparin and chondroitin sulfates in normal human plasma. Biochim Biophys Acta 1995, 1243: 49-58.
21. Al-Hakim A, Linhardt RJ. Electrophoresis and detection of nanogram quantities of exogenous and endogenous glycosaminoglycans in biological fluids. Appl and Theor Electrophoresis 1991; 1: 305-12.
22. Staprans I, Felts JM. Isolation and characterization of glycosaminoglycans in human plasma. J Clin Invest 1985; 76: 1984-91.
23. Rice KG, Rottink MK, Linhardt RJ. Fractionation of heparin-derived oligosaccharides by gradient polyacrylamide-gel electrophoresis. Biochem J 1987; 244: 515-22.
24. Heinegard D, Sommarin Y. Isolation and characterization of proteoglycans. Methods in Enzymol 1987; 144: 319-72.
25. Whitley CB, Ridnour MD, Draper KA, Dutton CM, Neglia JP. Diagnostic test for mucopolysaccharidosis. I. Direct method for quantifying excessive urinary glycosaminoglycan excretion. Clin Chem 1989; 35: 374-9.
26. Dupouy D, Sié P, Dol F, Boneu B. A simple method to measure dermatan sulfate at submicrogram concentrations in plasma. Thromb Haemost 1988; 60: 236-9.
27. Volpi N. Characterization of heparins with different relative molecular masses (from 11600 to 1600) by various analytical techniques. J Chrom Biomed Appl 1993; 622: 13-20.
28. Pescador R, Diamantini G, Mantovani M, Malandrino S, Riva A, Casu B, Oreste P. Absorption by the rat intestinal tract of fluorescein-labelled pig duodenal glycosaminoglycans. Arzneim-Forsch 1980; 30: 1893-6.
29. Larsen AK, Lund DP, Langer R, Folkman J. Oral heparin results in the appearance of heparin fragments in the plasma of rats. Proc Natl Acad Sci USA 1986; 83: 2964-8.
30. Palmieri L, Conte A, Giovannini L, Lualdi P, Ronca G. Metabolic fate of exogenous chondroitin sulfate in the experimental animal. Arzneim-Forsch 1990; 40: 319-23.
31. Conte A, de Bernardi M, Palmieri L, Lualdi P, Mautone G, Ronca G. Metabolic fate of exogenous chondroitin sulfate in man. Arzneim-Forsch 1991; 41: 768-72.
32. Baici A, Horler D, Moser B, Hofer HO, Fehr K, Wagenhauser FJ. Analysis of glycosaminoglycans in human serum after oral administration of chondroitin sulfate. Rheumatol Int 1992; 12: 81-8.
33. Crepaldi G, Rossi A, Coscetti G, Abbruzzese E, Calveri U, Calabrò A. Sulodexide oral administration influences blood viscosity and fibrinolysis. Drugs Exptl Clin Res 1992; 18: 189-95.
34. Scagnol I, Fumagalli G, Andriuoli G. Anticoagulant and antithrombotic activity of heparin salts by intraduodenal route in rabbits. Thromb Res 1992; 68: 195-200.
35. Jaques LB, Hiebert LM, Wice SM. Evidence from endothelium of gastric absorption of heparin and of dextran sulfates 8000. J Lab Clin 1991; 117: 122-30.
36. Fioravanti A, Franci A, Anselmi F, Fattorini L, Marcolongo R. Clinical efficacy and tolerance of galactosaminoglucuronoglycan sulfate in the treatment of osteoarthritis. Drugs Exptl Clin Res 1991; XVII: 41-4.
37. Vasdev S, Sampson CA, Longerich L, Parai S. Oral heparin prevents hypertension and elevated cytosolic calcium in salt-sensitive rats. Artery 1992, 19: 225-45.
38. Baggio B, Gambaro G, Marzaro G, Marchini F, Borsatti A, Crepaldi G. Effects of the oral administration of glycosaminoglycans on cellular abnormalities associated with idiopathic calcium oxalate nephrolithiasis. Eur J Clin Pharm 1991; 40: 237-40.